> A Chicago real estate developer has mapped out plans to create a new biotech cluster. Report
> A new study indicates that a genetic test for breast cancer can fail to detect mutations that can trigger the disease. Women from families with multiple breast and ovarian cancer cases are most at risk of a false positive. Article
> An FDA expert committee is meeting today to review a small number of adverse psychiatric risks linked to ADHD drugs and how those risks should best be conveyed to the public. Report
> Shares of Sanofi-Aventis surged on news that it had inked a deal with generic drug maker Apotex that could maintain its patent on the blockbuster blood thinner Plavix until 2011. Report
> APT Pharmaceuticals has raised $9 million in its first round of venture capital. Release
> Dennis Purcell, a senior managing director of Aisling Capital II, talks about how he picks biotech companies to invest in. Report
> Genmab says an early-stage trial of Humax CD-20 for rheumatoid arthritis demonstrated positive results. Report
> The FDA has provided orphan drug status to the Avicena Group's HD-02, the company's proprietary drug candidate for the treatment of Huntington's disease. Release
> Novelos Therapeutics has filed an IND for NOV-205, an experimental therapy for chronic hepatitis C. Release
> Perrigo has received FDA approval to sell a generic version of Ortho-McNeil Pharmaceutical's Terazol 3 Vaginal Suppositories. Report
> Neurobiological Technologies has launched a second Phase III trial of its stroke therapy Viprinex. Report
> ARIUS Research has licensed one of its antibodies to Genentech. Release
And Finally… Claims that cherries can treat or prevent disease has drawn a rebuke from the FDA. Article